| scholarly article | Q13442814 |
| P50 | author | Teresita M. Bellido | Q54855306 |
| P2093 | author name string | Lilian I Plotkin | |
| Stavros C Manolagas | |||
| Charles A O'Brien | |||
| Robert S Weinstein | |||
| Cara C Powers | |||
| Dan Jia | |||
| Scott A Stewart | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoblast | Q917177 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 1835-1841 | |
| P577 | publication date | 2003-12-22 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength | |
| P478 | volume | 145 |
| Q92665487 | 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy |
| Q34441705 | A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice |
| Q34089849 | A hypomagnetic field aggravates bone loss induced by hindlimb unloading in rat femurs |
| Q54569615 | A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: roles of extracellular signal-regulated kinase 1/2 and nuclear factor-κB. |
| Q92512052 | A soluble bone morphogenetic protein type 1A receptor fusion protein treatment prevents glucocorticoid-Induced bone loss in mice |
| Q43794059 | ATP and UTP stimulate bone morphogenetic protein-2,-4 and -5 gene expression and mineralization by rat primary osteoblasts involving PI3K/AKT pathway |
| Q94602644 | Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial |
| Q35850425 | Actions and interactions of estradiol and glucocorticoids in cognition and the brain: Implications for aging women. |
| Q45797594 | Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes |
| Q37685395 | Administration of erythropoietin exerts protective effects against glucocorticoid-induced osteonecrosis of the femoral head in rats |
| Q47778646 | Administration of erythropoietin prevents bone loss in osteonecrosis of the femoral head in mice |
| Q35878806 | Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. |
| Q34975913 | Advances in glucocorticoid-induced osteoporosis |
| Q41917846 | Aging, Osteocytes, and Mechanotransduction. |
| Q35650335 | Apoptosis associated with Wnt/β-catenin pathway leads to steroid-induced avascular necrosis of femoral head |
| Q43485164 | Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study |
| Q51741238 | Are glucocorticoids harmful to bone in early rheumatoid arthritis? |
| Q35643817 | Association of microstructural and mechanical properties of cancellous bone and their fracture risk assessment tool scores |
| Q50090300 | Autophagy as a target for glucocorticoid-induced osteoporosis therapy |
| Q37140444 | BMP-2 vs. BMP-4 expression and activity in glucocorticoid-arrested MC3T3-E1 osteoblasts: Smad signaling, not alkaline phosphatase activity, predicts rescue of mineralization |
| Q41880444 | Bcl2 deficiency activates FoxO through Akt inactivation and accelerates osteoblast differentiation |
| Q38221612 | Bisphosphonates and connexin 43: a critical review of evidence |
| Q40482310 | Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. |
| Q42684183 | Bone Microarchitecture and Biomechanics of the Necrotic Femoral Head |
| Q35853300 | Bone density and cortical structure after pediatric renal transplantation |
| Q64275098 | Bone function, dysfunction and its role in diseases including critical illness |
| Q36892518 | Bone health and the female athlete triad in adolescent athletes. |
| Q46284598 | Bone health in children and adolescents with steroid-sensitive nephrotic syndrome assessed by DXA and QUS. |
| Q89842071 | Bone in heart failure |
| Q91601705 | Bone morbidity in pediatric acute lymphoblastic leukemia |
| Q38149092 | Bone quality: the determinants of bone strength and fragility. |
| Q34463986 | Buried alive: how osteoblasts become osteocytes |
| Q34418734 | CCL7 is a protective factor secreted by mechanically loaded osteocytes |
| Q28067045 | Cell Death in Chondrocytes, Osteoblasts, and Osteocytes |
| Q84230841 | Changes in osteocyte density correspond with changes in osteoblast and osteoclast activity in an osteoporotic sheep model |
| Q83705714 | Children with protein-losing enteropathy after the Fontan operation are at risk for abnormal bone mineral density |
| Q47605221 | Chronic psychosocial stress disturbs long-bone growth in adolescent mice |
| Q34079475 | Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation |
| Q37111174 | Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo |
| Q27300741 | Control of bone mass and remodeling by PTH receptor signaling in osteocytes |
| Q36782248 | Core level regulatory network of osteoblast as molecular mechanism for osteoporosis and treatment |
| Q36261145 | Corticosteroid Is Associated with Both Hip Fracture and Fracture-Unrelated Arthropathy |
| Q37461733 | Corticosterone regulates the expression of neuropeptide Y and reelin in MLO-Y4 cells |
| Q55037768 | Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis in vivo and in vitro. |
| Q57712750 | Defining osteoblast and adipocyte lineages in the bone marrow |
| Q37059660 | Deletion of Cx43 from osteocytes results in defective bone material properties but does not decrease extrinsic strength in cortical bone |
| Q42700356 | Dexamethasone Exposure Accelerates Endochondral Ossification of Chick Embryos Via Angiogenesis |
| Q42756890 | Dexamethasone affects Fas- and serum deprivation-induced cell death of human osteoblastic cells through survivin regulation |
| Q41331999 | Dicer ablation in osteoblasts by Runx2 driven cre-loxP recombination affects bone integrity, but not glucocorticoid-induced suppression of bone formation |
| Q37137470 | Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome |
| Q50930225 | Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. |
| Q38852430 | Edaravone protects osteoblastic cells from dexamethasone through inhibiting oxidative stress and mPTP opening |
| Q42920668 | Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women |
| Q38603477 | Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease |
| Q47427456 | Effect of β‑ecdysterone on glucocorticoid‑induced apoptosis and autophagy in osteoblasts |
| Q42182743 | Effects of Ethyl Acetate Extract of Poncirus trifoliata Fruit for Glucocorticoid-Induced Osteoporosis |
| Q36103869 | Effects of NSAIDs on the osteogenic differentiation of human adipose tissue-derived stromal cells |
| Q47847091 | Effects of daily restraint with and without injections on skeletal properties in C57BL/6NHsd mice. |
| Q46502456 | Effects of genistein on vertebral trabecular bone microstructure, bone mineral density, microcracks, osteocyte density, and bone strength in ovariectomized rats |
| Q43182331 | Effects of glucocorticoid treatment on bone strength |
| Q88767677 | Effects of probiotic supplementation on performance traits, bone mineralization, cecal microbial composition, cytokines and corticosterone in laying hens |
| Q36510656 | Effects of prolonged high phosphorus diet on phosphorus and calcium balance in rats |
| Q36832823 | Effects of sodium ferulate on preventing steroid-induced femoral head osteonecrosis in rabbits |
| Q35755106 | Endogenous Glucocorticoids and Bone. |
| Q33806970 | Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice |
| Q51695975 | Expression characteristic and significance of interleukin-6, nuclear factor kappa beta, and bone formation markers in rat models of osteoporosis. |
| Q33289555 | Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development |
| Q39377326 | Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. |
| Q28385120 | From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis |
| Q30455468 | Fullerol antagonizes dexamethasone-induced oxidative stress and adipogenesis while enhancing osteogenesis in a cloned bone marrow mesenchymal stem cell |
| Q55714899 | GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling. |
| Q38232324 | GILZ: a new link between the hypothalamic pituitary adrenal axis and rheumatoid arthritis? |
| Q89375292 | GLUCOCORTICOID EXCESS IN BONE AND MUSCLE |
| Q49379739 | Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the NRF2 signaling pathway |
| Q36232568 | Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice |
| Q37230770 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate |
| Q46590090 | Glucocorticoid Suppresses Connexin 43 Expression by Inhibiting the Akt/mTOR Signaling Pathway in Osteoblasts |
| Q35225093 | Glucocorticoid dose determines osteocyte cell fate |
| Q36625707 | Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome |
| Q37482220 | Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice |
| Q34311717 | Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells |
| Q33716893 | Glucocorticoid receptor-mediated cis-repression of osteogenic genes requires BRM-SWI/SNF. |
| Q37714895 | Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis |
| Q91972306 | Glucocorticoid-Induced Bone Fragility Is Prevented in Female Mice by Blocking Pyk2/Anoikis Signaling |
| Q51093091 | Glucocorticoid-Induced Osteoporosis. |
| Q38227083 | Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment |
| Q35831218 | Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. |
| Q35229838 | Glucocorticoid-induced autophagy in osteocytes |
| Q37003240 | Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization |
| Q34240713 | Glucocorticoid-induced osteonecrosis |
| Q26778272 | Glucocorticoid-induced osteoporosis |
| Q35972062 | Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells? |
| Q36157622 | Glucocorticoid-induced osteoporosis and osteonecrosis |
| Q26821908 | Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency |
| Q38073889 | Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions |
| Q38195432 | Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. |
| Q36848804 | Glucocorticoid-induced osteoporosis: pathophysiology and therapy |
| Q35634073 | Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice |
| Q47930197 | Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases |
| Q35674916 | Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density |
| Q37200430 | Glucocorticoids and osteocyte autophagy |
| Q35639657 | Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts |
| Q57298071 | Glucocorticoids cause mandibular bone fragility and suppress osteocyte perilacunar-canalicular remodeling |
| Q37476212 | Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. |
| Q42514385 | Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis |
| Q50128187 | Glucocorticoids, Inflammation and Bone |
| Q33665237 | Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity |
| Q36246088 | Glucocorticoids: bad or safe for the bones? |
| Q33282690 | Glucocorticosteroid-induced osteoporosis in adult primiparous Göttingen miniature pigs: effects on bone mineral and mineral metabolism |
| Q35601856 | Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment |
| Q57028364 | Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis |
| Q92028467 | Haem oxygenase-1 induction prevents glucocorticoid-induced osteoblast apoptosis through activation of extracellular signal-regulated kinase1/2 signalling pathway |
| Q47821592 | Histomorphometric and osteocytic characteristics of cortical bone in male subtrochanteric femoral shaft. |
| Q90125643 | Hydrogen sulfide is a novel regulator implicated in glucocorticoids-inhibited bone formation |
| Q55514038 | Hypersensitivity to orthopaedic implant manifested as erythroderma: Timing of implant removal☆. |
| Q53670887 | IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. |
| Q45017800 | Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? |
| Q44774590 | Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. |
| Q35056142 | Inhaled corticosteroids and bone health |
| Q46381374 | Inhibin and the regulation of bone mass |
| Q33874504 | Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice |
| Q38738551 | International Consensus Statement on Allergy and Rhinology: Rhinosinusitis |
| Q52678219 | Intramembranous ossification and endochondral ossification are impaired differently between glucocorticoid-induced osteoporosis and estrogen deficiency-induced osteoporosis. |
| Q36088373 | Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures? |
| Q36592819 | Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling |
| Q92398318 | Local controlled release of corticosteroids extends surgically induced joint instability by inhibiting tissue healing |
| Q37408472 | Long-term therapy in COPD: any evidence of adverse effect on bone? |
| Q36785422 | Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage |
| Q38978699 | Low-trauma fractures without osteoporosis |
| Q30973924 | METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-κB signaling pathway. |
| Q46957183 | MKP-1 knockout does not prevent glucocorticoid-induced bone disease in mice |
| Q89656964 | Magnesium and vitamin C supplementation attenuates steroid-associated osteonecrosis in a rat model |
| Q36255238 | Male osteoporosis: new trends in diagnosis and therapy |
| Q30946308 | Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk |
| Q35026459 | Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options |
| Q37230323 | Management of glucocorticoids-induced osteoporosis: role of teriparatide |
| Q40426618 | Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs |
| Q26798296 | Mechanism and Treatment Strategy of Osteoporosis after Transplantation |
| Q37341018 | Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis |
| Q36817218 | Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease |
| Q37499649 | Minireview: live and let die: molecular effects of glucocorticoids on bone cells. |
| Q97569060 | Mitochondrial dysfunction impairs osteogenesis, increases osteoclast activity, and accelerates age related bone loss |
| Q38721980 | Molecular Actions of Glucocorticoids in Cartilage and Bone During Health, Disease, and Steroid Therapy. |
| Q36016775 | Molecular and cellular mechanisms of the anabolic effect of intermittent PTH |
| Q55261693 | Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture. |
| Q57468262 | Myostatin and other musculoskeletal markers in lung transplant recipients |
| Q64114533 | NADPH Oxidase Isoforms Are Involved in Glucocorticoid-Induced Preosteoblast Apoptosis |
| Q35125905 | Neurexophilin 1 suppresses the proliferation of hematopoietic progenitor cells |
| Q34027668 | New insights into the pathogenesis of glucocorticoid-induced avascular necrosis: microarray analysis of gene expression in a rat model. |
| Q34576635 | Nothing but skin and bone |
| Q37083734 | Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates. |
| Q37952851 | Optimal management of cancer treatment-induced bone loss: considerations for elderly patients |
| Q37113417 | Optimum management of glucocorticoid-treated patients. |
| Q36357864 | Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. |
| Q38058755 | Osteocalcin: skeletal and extra-skeletal effects |
| Q36759428 | Osteocyte apoptosis |
| Q34017216 | Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency |
| Q39070090 | Osteocyte-induced angiogenesis via VEGF-MAPK-dependent pathways in endothelial cells. |
| Q37702067 | Osteocytes and WNT: the mechanical control of bone formation. |
| Q36587647 | Osteocytes--martyrs for integrity of bone strength |
| Q37958204 | Osteocytes: central conductors of bone biology in normal and pathological conditions |
| Q88900139 | Osteoporosis following heart transplantation and immunosuppressive therapy |
| Q35175707 | Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice |
| Q35174737 | Ovariectomy enhances mechanical load-induced solute transport around osteocytes in rat cancellous bone |
| Q50933551 | Overexpression of BCLXL in Osteoblasts Inhibits Osteoblast Apoptosis and Increases Bone Volume and Strength. |
| Q34082775 | Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis |
| Q91680207 | Overexpression of WNT16 Does Not Prevent Cortical Bone Loss Due to Glucocorticoid Treatment in Mice |
| Q39016683 | P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone-induced death of osteoblasts |
| Q37430269 | Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders |
| Q90305123 | Phenomenon of osteocyte lacunar mineralization: indicator of former osteocyte death and a novel marker of impaired bone quality? |
| Q35725177 | Plumbagin protects against glucocorticoid-induced osteoporosis through Nrf-2 pathway |
| Q52568369 | Pravastatin Protects Against Avascular Necrosis of Femoral Head via Autophagy. |
| Q88614967 | Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center |
| Q88815365 | Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice |
| Q34153085 | Prevalence and risk factors of vertebral compression fractures in female SLE patients |
| Q35108990 | Prevention of glucocorticoid induced-apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice |
| Q39177137 | Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations. |
| Q47977236 | Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin |
| Q41655841 | Protective effect of Korean Red Ginseng against glucocorticoid-induced osteoporosis in vitro and in vivo |
| Q37527813 | Protective effect of VK2 on glucocorticoid-treated MC3T3-E1 cells |
| Q61143721 | Ptychographic X-ray CT characterization of the osteocyte lacuno-canalicular network in a male rat's glucocorticoid induced osteoporosis model |
| Q35865816 | Quantitative proteomic analysis of dexamethasone-induced effects on osteoblast differentiation, proliferation, and apoptosis in MC3T3-E1 cells using SILAC |
| Q28270738 | Recognizing and treating secondary osteoporosis |
| Q85941935 | Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study |
| Q92988138 | Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans |
| Q50623650 | Regulatory effect of microRNA-34a on osteogenesis and angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head. |
| Q37616728 | Retrospective study of absorbable gelatin sponge soaked in triamicinolone acetonide as interpositioning material in temporomandibular joint ankylosis in 350 patients |
| Q46907008 | Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats |
| Q35838962 | Risk factors for prevalent vertebral fractures in black and white female densitometry patients |
| Q37172756 | Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone |
| Q88623230 | Role of Teriparatide in Glucocorticoid-induced Osteoporosis through Regulating Cellular Reactive Oxygen Species |
| Q34235921 | Role of teriparatide in treatment of glucocorticoid-induced osteoporosis |
| Q54035461 | Sclerostin Blockade-A Dual Mode of Action After All? |
| Q36315274 | Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor |
| Q35408354 | Set-up of a multivariate approach based on serum biomarkers as an alternative strategy for the screening evaluation of the potential abuse of growth promoters in veal calves |
| Q35065044 | Skeletal health of children and adolescents with inflammatory bowel disease |
| Q35058081 | Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids |
| Q37133892 | Skeletal involvement in adult patients with endogenous hypercortisolism |
| Q36356669 | Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of β-catenin |
| Q79379073 | Skeletal unloading induces osteoblast apoptosis and targets alpha5beta1-PI3K-Bcl-2 signaling in rat bone |
| Q30433764 | Steroid effects on osteogenesis through mesenchymal cell gene expression |
| Q52584259 | Steroid-associated osteonecrosis animal model in rats. |
| Q46276637 | Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response |
| Q36718805 | Structural basis of growth-related gain and age-related loss of bone strength |
| Q41785572 | Sulforaphane reverses glucocorticoid-induced apoptosis in osteoblastic cells through regulation of the Nrf2 pathway |
| Q35286818 | Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone |
| Q36929011 | Suppression of autophagy in osteocytes mimics skeletal aging |
| Q36633247 | Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis |
| Q36375631 | Tanshinone IIA blocks dexamethasone-induced apoptosis in osteoblasts through inhibiting Nox4-derived ROS production |
| Q36372606 | Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass |
| Q47761381 | The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice |
| Q38820789 | The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors |
| Q48026063 | The ability of H1 or H2 receptor antagonists or their combination in counteracting the glucocorticoid-induced alveolar bone loss in rats. |
| Q37715744 | The association of time and medications with changes in bone mineral density in the 2 years after critical illness |
| Q38930944 | The biochemical signatures of stress: A preliminary analysis of osteocalcin concentrations and macroscopic skeletal changes associated with stress in the 13th - 17th centuries black friars population |
| Q104795072 | The critical role of T cells in glucocorticoid-induced osteoporosis |
| Q54328009 | The effect of electromagnetic fields on the proliferation and the osteogenic or adipogenic differentiation of mesenchymal stem cells modulated by dexamethasone. |
| Q36314303 | The effects of piper sarmentosum water extract on the expression and activity of 11β-hydroxysteroid dehydrogenase type 1 in the bones with excessive glucocorticoids. |
| Q38168952 | The intelligent use of systemic glucocorticoids in rheumatoid arthritis |
| Q38050401 | The multiple facets of glucocorticoid action in rheumatoid arthritis |
| Q37203605 | The osteocyte: an endocrine cell ... and more |
| Q36177496 | The past, present, and future of bone morphometry: its contribution to an improved understanding of bone biology |
| Q88802431 | The role of autophagy in steroid necrosis of the femoral head: a comprehensive research review |
| Q91729090 | The shift in the balance between osteoblastogenesis and adipogenesis of mesenchymal stem cells mediated by glucocorticoid receptor |
| Q38945640 | The standardized creation of a lumbar spine vertebral compression fracture in a sheep osteoporosis model induced by ovariectomy, corticosteroid therapy and calcium/phosphorus/vitamin D-deficient diet. |
| Q64937734 | Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density. |
| Q48170330 | Towards understanding the dose and timing effect of hydrocortisone treatment on the scleral ossicle system within the chicken eye. |
| Q36658975 | Transplantation osteoporosis |
| Q84567655 | Treating osteonecrosis with autologous bone marrow cells |
| Q48908924 | Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? |
| Q83599293 | Ultrastructural characteristics of glucocorticoid-induced osteoporosis |
| Q38213973 | Utility of the trabecular bone score (TBS) in secondary osteoporosis |
| Q52728308 | Valproic acid prevents glucocorticoid‑induced osteonecrosis of the femoral head of rats. |
| Q50959482 | Vitamin D in nephrotic syndrome remission: a case-control study. |
| Q36727078 | Vitamin K2 Prevents Glucocorticoid-induced Osteonecrosis of the Femoral Head in Rats |
| Q43268923 | Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome |
| Q36751589 | miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway |
Search more.